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Abstract: We have previously demonstrated that the small leucine-rich proteoglycan decorin 
may play a role in adipose tissue homeostasis and the pathophysiology of obesity. Biglycan is 
highly similar in structure to decorin, therefore we hypothesized it would have a similar expres-
sion profile and role to decorin in adipose tissue. Real time polymerase chain reaction was used 
to measure biglycan mRNA levels in adipose tissue from normal glucose tolerant and impaired 
glucose tolerant and type 2 diabetic (T2D) Psammomys obesus. Biglycan mRNA was found to 
be highly expressed in adipose tissue, and gene expression was significantly higher in visceral 
compared to subcutaneous adipose tissue, with elevated levels in obese, T2D compared to lean 
normal glucose tolerant P . obesus (P , 0.04). Biglycan mRNA was predominantly expressed 
by stromal/vascular cells of fractionated adipose tissue (P = 0.023). Biglycan expression in 
adipose tissue, particularly in the obese state, was markedly upregulated. Collectively, our 
data suggest that the small leucine-rich proteoglycan family proteins biglycan and decorin 
may play a role in the development of obesity and T2D, possibly by facilitating expansion of 
adipose tissue mass.
Keywords: biglycan, small leucine-rich proteoglycan, Psammomys obesus, adipose tissue, 
obesity, type 2 diabetes
Introduction
We previously identified the small leucine-rich proteoglycan (SLRP) decorin as a 
secreted protein not previously associated with the development of obesity, type 2 
diabetes (T2D), and the metabolic syndrome.1 Decorin was highly expressed in adipose 
tissue, with significantly higher gene expression in visceral compared to subcutaneous 
adipose tissue depots in both Psammomys obesus and human subjects (P = 0.002 and 
P = 0.001, respectively).1 Furthermore, decorin was shown to be expressed adjacent 
to blood vessels in the adipose tissue.1 These findings suggest that this SLRP may play 
a role in adipose tissue homeostasis and in the pathophysiology of obesity.
Biglycan is a SLRP closely related to decorin, with sequence and structure analysis 
showing the genes are 55% homologous at the amino acid level and are most likely a 
product of gene duplication.2 Like decorin, biglycan binds transforming growth factor 
β3 and interacts with collagen.4 The similarity in structure and overlapping expression 
profiles in skeletal muscle and connective tissues suggest that it is likely that these two 
proteins function redundantly and synergistically.5–7 The targeted disruption of deco-
rin in mice results in mice with fragile skin, reduced tensile strength, and abnormal 
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  collagen morphology,8 whereas biglycan knockout mice have 
an osteoporosis-like phenotype.9 The biglycan knockout mice 
are born with no apparent defects however after 3 months 
they have a reduced growth rate and decreased bone mass 
suggesting biglycan is a postnatal regulator of skeletal mass.9 
Previous studies investigating the biglycan,9 decorin,8 and 
biglycan/decorin10 deficient mouse models have suggested 
that these two genes may have redundant functions, and fur-
thermore, may compensate for each other’s functions when 
one of them is deficient.6,11 Mice deficient in decorin and 
biglycan exhibit a more severe phenotype than mice deficient 
in either gene alone.10 Biglycan and decorin therefore may 
partly rescue or compensate for each other’s absence in the 
singly deficient mice.7,11–13
Given the expression and functional similarity between 
decorin and biglycan, the aim of this study was to characterize 
biglycan in relation to obesity and T2D in P . obesus.
Materials and methods
Experimental animals
A colony of P . obesus were maintained at Deakin Univer-
sity as previously described.1 At 16 weeks of age, animals 
were classified into three groups according to their blood 
glucose and plasma insulin concentrations.1,14 The groups 
were as follows: (1) lean and normal glucose tolerant (NGT), 
(2) overweight and impaired glucose tolerant (IGT), and 
(3) obese, T2D. Phenotypic characteristics of each group 
are previously published.1 At 18 weeks of age, animals were 
killed by anesthetic overdose (pentobarbitone, 120 mg/kg; 
Sigma, St Louis, MO) and tissues were rapidly excised, snap 
frozen in liquid nitrogen, and stored at −80°C for subsequent 
RNA extraction. All experiments were conducted accord-
ing to strict National Health and Medical Research Council 
guidelines and approved by the Deakin University Animal 
Welfare Committee.
RnA extraction
Total RNA was extracted from P . obesus (n = 5–6 per group) 
tissues using TRIzol (Invitrogen, Carlsbad, CA) in conjunc-
tion with RNeasy columns (Qiagen, Hilden, Germany). The 
quality and concentration of RNA was determined using the 
RNA 6000 Nano Assay and an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Total RNA was 
extracted in this study from the following tissues: testes; lung, 
small and large intestine; adrenal; spleen; kidney; stomach; 
heart; perirenal, mesenteric, epididymal, intramuscular, 
and subscapular adipose tissue; soleus, extensor digitorum 
longus, plantaris, white and red gastrocnemius; liver; brain 
stem, mid brain, hippocampus, cerebellum, cortex, and 
hypothalamus. With regards to adipose tissue depots, brown 
adipose tissue depots were excised and discarded in order to 
freeze only the white adipose tissue in each depot type. The 
intramuscular fat originates from a fat depot associated with 
the gastrocnemius muscle.
Real time polymerase chain reaction
First strand cDNA was generated from RNA using Super-
Script First-Strand Synthesis System (Invitrogen) for real 
time polymerase chain reaction (RT-PCR). Biglycan gene 
expression levels were quantitated using SYBR Green PCR 
Master Mix (Applied Biosystems, Worthington, UK) with 
an ABI PRISM 7700 Sequencing Detector (Perkin Elmer, 
Waltham, MA). Arbitrary units (AU) were calculated using 
the delta cycle threshold method. Gene expression was 
normalized to the group of samples with the lowest mean 
cycle threshold. RT-PCR primers were as follows: P . obesus 
biglycan   forward 5′-GACAACCGTATCCGCAAAGTG -3′, 
reverse 5′-GAGCTTCAGGCCATCAAAGG -3′.
Adipose tissue fractionation
P . obesus (n = 5) were sacrificed and the epididymal adipose 
tissue was removed and digested with type I colleganse 
digestion as previously described.1 Fractions were frozen in 
liquid nitrogen for subsequent RNA extraction and RT-PCR 
as described above.
Statistical analysis
Statistical analysis was performed using SPSS (v 14.0; SPSS 
Inc, Chicago, IL). Levene’s test for homogeneity of variance 
was used to determine if variance between two groups was 
equal. As homogeneity was equal, a one-way analysis of vari-
ance with a post hoc least significant difference test was used. 
Associations between gene expression levels and phenotypic 
measures were determined using Pearson’s correlation for 
normally distributed data or Spearman’s correlation for 
data that were not normally distributed. To compare mean 
phenotypic values between groups, independent samples 
t-test was used. Differences and correlations were considered 
significant at P , 0.05.
Results
Biglycan is highly expressed in adipose 
tissue from P. obesus
Biglycan gene expression was analyzed in a variety of tis-
sues from P . obesus, an animal model of obesity and T2D. 
Similar to decorin, biglycan had markedly higher expression 
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within adipose tissue depots compared with all other tissues 
examined (Figure 1). Biglycan was also expressed at lower 
levels in the brain, liver, red gastrocnemius, heart, stomach, 
kidney, spleen, adrenal, lung, and testes.
Due to the remarkable expression within adipose tissue 
depots, biglycan gene expression was next analyzed in vis-
ceral (mesenteric) and subcutaneous (subscapular) adipose 
tissue of P . obesus by RT-PCR. Biglycan expression was 
higher in visceral compared to subcutaneous adipose tissue 
overall (P = 0.038, gene expression (mean AU ± standard 
error of mean): visceral 655 ± 123, subcutaneous 357 ± 61). 
In P . obesus with impaired glucose tolerance, biglycan gene 
expression was significantly higher in visceral compared 
with subcutaneous adipose tissue (P = 0.049, Figure 2A). 
Separately, within subcutaneous tissue, biglycan gene expres-
sion was significantly elevated in IGT and T2D P . obesus 
compared with healthy (NGT) littermates (P = 0.009 and 
P , 0.001, respectively) and significantly correlated with 
body weight (r2 = 0.38, P = 0.012), plasma glucose, and 
insulin concentration (r2 = 0.38, P = 0.011 and r2 = 0.29, 
P = 0.031, respectively), and percentage body fat (r2 = 0.50, 
P = 0.003). Biglycan gene expression was significantly 
elevated in visceral T2D compared to NGT (P = 0.002) and 
was significantly correlated with body weight (r2 = 0.31, 
P = 0.024), plasma glucose concentration (r2 = 0.46, 
P = 0.004), and percentage body fat (r2 = 0.38, P = 0.014) 
in visceral adipose tissue. This expression profile was similar 
to that of decorin.
Biglycan gene expression was measured in the same NGT, 
IGT, and T2D mesenteric and subscapular adipose tissue 
samples as decorin. This allowed us to analyze a potential 
association between the two genes during the development of 
obesity and T2D. Bivariate analysis revealed a strong correla-
tion between decorin and biglycan gene expression (r2 = 0.86, 
P , 0.001) during the development of obesity and T2D in 
P . obesus mesenteric and subscapular adipose tissue.
Biglycan is predominantly expressed 
within stromal/vascular cells  
in fractionated adipose tissue
To determine which cells in adipose tissue express biglycan, gene 
expression was measured in fractionated   epididymal adipose 
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Figure 1 Biglycan gene expression in a variety of P. obesus tissues.
Notes: RnA was extracted from a variety of tissues from T2D P. obesus and gene expression measured by RT-PCR. Biglycan expression is represented relative to 
hypothalamic expression.
Abbreviations: P. obesus, Psammomys obesus; IM, intramuscular; EDL, extensor digitorum longus; gastroc, gastrocnemius; T2D, type 2 diabetes; RT-PCR, real time 
polymerase chain reaction.
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tissue from IGT P . obesus. There were two   cellular   populations 
– adipocytes and stromal/vascular cells.   Comparable to decorin 
which had almost exclusive expression within stromal/vascular 
cells, biglycan was   predominantly expressed in stromal/vascular 
cells compared to adipocytes (P = 0.023, Figure 2B). Suc-
cessful fractionation was confirmed using adipocyte-specific 
(leptin) and stromal/vascular-specific (CD68, Pref-1) markers. 
As expected, leptin gene expression was significantly higher 
in the adipocyte compared to the stromal/vascular fraction 
(P , 0.001), and CD68/Pref-1 gene expression was signifi-
cantly higher in the stromal/vascular compared to adipocyte 
fraction (P , 0.001; data not shown).
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Figure 2A Analysis of biglycan gene expression in P. obesus visceral and subcutaneous adipose tissue.
Notes: RnA was extracted from visceral (mesenteric) and subcutaneous (subscapular) adipose tissue of ngT, IgT and T2D P. obesus and biglycan gene expression measured 
by RT-PCR. Data are mean ± SEM (n = 5–6 per group). Data is represented relative to expression in ngT subcutaneous adipose tissue. *P = 0.049 compared to subcutaneous 
IgT; ^P = 0.009, †P , 0.001 compared to subcutaneous ngT, respectively; #P = 0.002 compared to visceral ngT.
Abbreviations: P. obesus, Psammomys obesus; ngT, normal glucose tolerant; IgT, impaired glucose tolerant; T2D, type 2 diabetes; RT-PCR, real time polymerase chain 
reaction; SEM, standard error of mean.
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Figure 2B Biglycan expression in fractionated P. obesus epididymal adipose tissue.
Notes: Epididymal adipose tissue from P. obesus was fractionated into adipocytes and stromal/vascular cells and gene expression measured by RT-PCR. Data are mean ± SEM 
(n = 5 per group). Overall, biglycan gene expression was significantly higher in the stromal/vascular compared to adipocyte fraction (*P , 0.023).
Abbreviations: P. obesus, Psammomys obesus; RT-PCR, real time polymerase chain reaction; SEM, standard error of mean.
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Discussion
We have previously shown the SLRP decorin to be highly 
expressed in adipose tissue, and upregulated in obesity sug-
gesting a potential role in adipose tissue homeostasis or in the 
pathophysiology associated with obesity such as extracellular 
matrix (ECM) remodeling, inflammation, and angiogenesis 
within expanding adipose tissue. Here we extend these find-
ings to include the closely related SLRP, biglycan, which also 
exhibits high expression in adipose tissue (and particularly 
visceral adipose tissue) compared to a wide variety of tissues 
examined, and increased expression in obesity.
Collectively, these data raise the possibility that increased 
expression of SLRPs in adipose tissue is a key feature   during 
the development of obesity, T2D, and the metabolic syn-
drome. SLRPs are constituents of the ECM which undergoes 
constant degradation and renewal,15 allows the diffusion of 
nutrients, metabolites, and hormones between blood and 
cells within the tissue16 and functions not only as a scaffold 
for cells within tissues, but also as a reservoir of growth fac-
tors and cytokines and modulates their activities.17 SLRPs 
bind and interact with numerous proteins involved in matrix 
assembly, cell proliferation, and tissue   morphogenesis.18 
With regards to adipocyte differentiation, remarkable 
changes in cell morphology, cytoskeletal components, and 
the amount and type of ECM components secreted occurs.19 
Furthermore, the development of obesity requires extensive 
reorganization of adipose tissue and the expression of genes 
involved in matrix remodeling was found to be increased in 
obese db/db mice and resulted in the net accumulation of 
ECM components in parallel to increased adipocyte size.20 
It has also been proposed that complications of diabetes are 
closely associated with changes in the ECM21,22 as macroan-
giopathic and microangiopathic complications resultant from 
the presence of diabetes have involved abnormalities within 
the extracellular intima.21
Given the above background information regarding 
SLRPs, it is therefore tempting to speculate that SLRPs 
may play a role in angiogenesis and ECM remodeling within 
expanding adipose tissue during the development of obesity 
and T2D. Recent studies have demonstrated biglycan to be 
upregulated in a murine model of diet-induced obesity with 
atherosclerosis,23 to be involved in vascular and proathero-
genic remodeling in a rat model of metabolic syndrome,24 
to be proangiogenic,25 and interestingly, to have upregulated 
expression in parallel with matrix degradation genes in white 
adipose tissue from db/db mice fed a high fat diet.20  Biglycan 
has also been demonstrated to be upregulated in human 
omental compared to lean adipose tissue.26 This evidence 
builds upon the hypothesized role for biglycan in adipose 
tissue homeostasis, particularly in states of obesity where 
ECM remodeling is required for adipose tissue expansion.
Biglycan has been shown to be proinflammatory and 
acts through toll-like receptors in macrophages.27–29 Recent 
studies have supported a strong association of biglycan 
with inflammation, demonstrating increased levels of tumor 
  necrosis factor α (a major inflammatory cytokine implicated 
in T2D) and   biglycan in human omental adipose tissue, sug-
gesting they may be coregulated.26 This potentially associates 
biglycan to obesity which is associated with a chronic low 
grade inflammatory state in adipose tissue (particularly visceral 
adipose tissue),30,31 and the subsequent development of insulin 
resistance and T2D.30 However, these are postulated theories, 
therefore additional experiments to explore a role in inflam-
mation and substantiate these theories are now required.
In summary, our data suggest that the family of SLRPs 
may play a role in the development of obesity and T2D, with 
a hypothesized role of facilitating the expansion of adipose 
tissue mass within an animal model. Further work is now 
required to corroborate these results within humans.
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